{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:04:14Z","timestamp":1792325054207,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1097\/01.mpa.0000235302.73615.d4","type":"journal-article","created":{"date-parts":[[2006,9,25]],"date-time":"2006-09-25T08:43:25Z","timestamp":1159173805000},"page":"250-254","source":"Crossref","is-referenced-by-count":36,"title":["Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid Tumors"],"prefix":"10.1097","volume":"33","author":[{"given":"Eugene A.","family":"Woltering","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth S.","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Zolfoghary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Zietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vay Liang W.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron I.","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etta","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"O'Dorisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg","family":"Mamikunian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl A","key":"R1-7-20210212","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000051853","article-title":"Tumor markers in neuroendocrine tumors.","volume":"62","author":"Eriksson","year":"2000","journal-title":"Digestion"},{"issue":"9","key":"R2-7-20210212","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s00268-004-7384-6","article-title":"Chromogranin A, a marker of the therapeutic success of neuroendocrine liver metastases: preliminary report.","volume":"28","author":"Sondenaa","year":"2004","journal-title":"World J Surg"},{"issue":"1-3","key":"R3-7-20210212","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.regpep.2004.03.017","article-title":"Chromogranin A as a determinant of midgut carcinoid tumor volume.","volume":"120","author":"Kolby","year":"2004","journal-title":"Regul Pept"},{"issue":"7","key":"R4-7-20210212","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/00365520410005225","article-title":"Treatment of enterochromagranin cell carcinoids with octreotide LAR.","volume":"39","author":"Fykse","year":"2004","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"R5-7-20210212","first-page":"641","article-title":"Chromogranin A: a marker of neuroendocrine tumors.","volume":"60","author":"D'Herbomez","year":"2002","journal-title":"Annales de Biologie Unique"},{"key":"R6-7-20210212","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"R7-7-20210212","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors: a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).","volume":"80","author":"Plockinger","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"suppl IV","key":"R8-7-20210212","first-page":"iv1","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.","volume":"54","author":"Ramage","year":"2005","journal-title":"Gut"},{"issue":"1","key":"R10-7-20210212","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/EP:14:1:3","article-title":"The chromogranins: Their role in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.","volume":"14","author":"Feldman","year":"2003","journal-title":"Endocr Pathol"},{"issue":"4","key":"R11-7-20210212","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/01.mpa.0000186249.89081.0d","article-title":"The effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.","volume":"31","author":"Woltering","year":"2005","journal-title":"Pancreas"},{"issue":"1","key":"R12-7-20210212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0002-9610(03)00115-6","article-title":"Serum peptide profiles in patients with carcinoid tumors.","volume":"186","author":"Calhoun","year":"2003","journal-title":"Am J Surg"},{"issue":"5","key":"R13-7-20210212","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2265.2004.02030.x","article-title":"Interest of Chromogranin A for diagnosis and follow up of endocrine tumours.","volume":"60","author":"Nehar","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R14-7-20210212","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-642-59587-5_4","article-title":"New molecular aspects in the diagnosis and therapy of neuroendocrine tumors of the gastroenteropancreatic system.","volume":"153","author":"Pape","year":"2000","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"R15-7-20210212","first-page":"1","article-title":"Biochemical diagnosis of gastroenteropancreatic endocrine tumors.","volume":"94","author":"Tartaglia","year":"2003","journal-title":"Minerva Med"},{"key":"R16-7-20210212","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0167-0115(00)00167-1","article-title":"Serum pacreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.","volume":"96","author":"Desai","year":"2001","journal-title":"Regul Pept"},{"issue":"9","key":"R17-7-20210212","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1445-2197.2002.02507.x","article-title":"Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumors.","volume":"72","author":"Rohaizak","year":"2002","journal-title":"ANZ J Surg"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006676-200610000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:13:13Z","timestamp":1618031593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-200610000-00007"}},"subtitle":["Lack of Correlation Between Absolute Chromogranin A Levels and Symptom Frequency"],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mpa.0000235302.73615.d4","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}